Randstad Sourceright Releases Report on Demand for Key Jobs in the US During COVID-19
This week, Randstad Sourceright released its report, “How is Key Talent in the US Impacted by COVID-19?” The report analyzes data from the Bureau of Labor Statistics, World Health Organization, job boards, career sites, and social media postings to map the demand for key jobs in the US.
The report identifies the changes in demand for key jobs across six job families between January 2019 and April 2020, one of which is chemistry (pharmaceutical R&D).
While there has been a 17% decrease in overall pharma R&D jobs from February to March, the demand for clinical research associates and trial managers has increased by 46%, making it one of the few industries that has had to increase hiring since the start of the pandemic. These were identified as the two most sought after roles in pharma R&D. It is projected that the pandemic will accelerate the shortage of talent and increase recruitment activities for these roles.
The report aims to identify the shift in demand for certain skills, which will inform employers on how to be more prepared to recruit and hire once things return to normal.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
